Good News At Last For GSK With Daprodustat, But Safety Scrutiny Awaits

Likely To Dominate US Market If Approved

GSK could gain a first-in-class approval for anemia in chronic kidney disease in the US, but approval and uptake of the HIF inhibitor in non-dialysis patients remain uncertain.

Dialysis patient
While HIF inhibitors could replace ESAs in dialysis patients, use in non-dialysis patients offers the greatest potential • Source: Alamy

GlaxoSmithKline looks likely to dominate the US market for new oral treatments for anemia in chronic kidney disease (CKD) after success for daprodustat in two Phase III studies, as long as it can convince US Food and Drug Administration experts on its safety.

Trial results comparing daprodustat with erythropoiesis-stimulating agents (ESAs) were presented on 5 November, and showed it to be non-inferior in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip